The startup operates a molecular imaging platform that utilizes non-invasive radiopharmaceutical imaging technology to detect early-stage colorectal, esophageal, and lung adenocarcinoma. This technology enables healthcare providers to make precise diagnoses and tailor cancer treatment plans, improving patient outcomes and care efficiency.
Funding
$2.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+10Founders
Product
Problem
Detecting early-stage colorectal, esophageal, and lung adenocarcinoma is challenging with traditional methods, potentially delaying diagnosis and treatment. Current diagnostic approaches may lack the precision needed for accurate staging and personalized treatment planning.
Solution
The startup offers a molecular imaging platform designed for the early detection of colorectal, esophageal, and lung adenocarcinoma. This platform employs non-invasive radiopharmaceutical imaging technology to visualize and characterize tumors at a molecular level. By providing detailed information about tumor biology, the technology enables healthcare providers to make more precise diagnoses and tailor cancer treatment plans to individual patients. The platform aims to improve patient outcomes and enhance the efficiency of cancer care by facilitating earlier intervention and more targeted therapies.
Target Audience
The primary audience includes healthcare providers, oncologists, and hospitals specializing in the diagnosis and treatment of colorectal, esophageal, and lung cancers.
Features
- Non-invasive radiopharmaceutical imaging for early cancer detection
- Molecular-level tumor characterization
- Enhanced diagnostic precision for accurate staging
- Personalized treatment planning based on individual tumor biology